Share chart Opthea Limited
Extended chart
Simple chart
About
Opthea Limited, биофармацевтическая компания, работающая на клинической стадии, разрабатывает и коммерциализирует терапию, в первую очередь, для лечения глазных болезней в Австралии. Деятельность компании по развитию основана на портфеле интеллектуальной собственности, включающем факторы роста эндотелия сосудов (VEGF), VEGF-C, VEGF-D и VEGF Receptor-3 для лечения заболеваний, связанных с ростом кровеносных и лимфатических сосудов, а также утечкой сосудов. .
More detailsP/S | 1568.2 |
---|---|
P/BV | 11.55 |
EV/EBITDA | -6.29 |
EBITDA | -0.0264 |
Число акций ао | 0.05869 млрд |
Цена ао | 4.63 |
Сайт | https://www.opthea.com |
ISIN | US68386J2087 |
Выручка | 0.000112 |
Валюта | usd |
IPO date | 2012-04-12 |
Sector | Health Care |
Industry | Biotechnology |
Валюта отчета | usd |
Change price per day: | 0% (5.13) |
---|---|
Change price per week: | +8.92% (4.71) |
Change price per month: | +62.86% (3.15) |
Change price per 3 month: | +140.85% (2.13) |
Change price per half year: | +50.88% (3.4) |
Change price per year: | +185.92% (1.7942) |
Change price per 3 year: | -35.47% (7.95) |
Change price per year to date: | +172.87% (1.88) |
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
Institutions | Volume | Share, % |
---|---|---|
Victory Capital Management Inc. | 856 | 1.59 |
Texas - Teacher Retirement System | 625 | 1.16 |
Frazier Financial Advisors, LLC | 355 | 0 |
Millennium Management LLC | 74 | 0.14 |
Bank of Montreal/Can/ | 53 | 0.1 |
Morgan Stanley | 21 | 0 |
Regal Partners Ltd. | 3 | 5.4 |
Baker Brothers Advisors, LLC | 2 | 4.05 |
ETF | Share, % | Profitability for 1 year, % | Dividends, % |
---|---|---|---|
SPDR S&P International Small Cap ETF | 0 | 8.9378151260504 | 3.10348 |
Vanguard ESG International Stock ETF | 0 | 10.20253643763 | 3.07501 |
Vanguard FTSE All-World ex-US Small-Cap ETF | 0.01 | 9.3937465915288 | 3.09932 |
Head | Job title | Payment | Year of birth |
---|---|---|---|
Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D. | Founder, Chief Innovation Officer & Executive Director | 599.73k | 1975 (49 years) |
Dr. Michael Gerometta Ph.D. | Head of Chemistry, Manufacturing & Controls Development | 129.16k | 1965 (59 years) |
Dr. Frederic Guerard M.S., Pharm.D. | Chief Executive Officer | N/A | 1972 (52 years) |
Dr. Kenneth Sall | Chief Medical Officer | N/A | |
Ms. Karen Adams CPA | VP of Finance & Company Secretary | 305.14k | 1971 (53 years) |
Ms. Sarika Gulhar Ph.D. | Executive Director of Human Resources | N/A | |
Dr. Fang Li Ph.D. | Senior Vice President of Regulatory Affairs | N/A | 1964 (60 years) |
Mr. Daniel E. Geffken M.B.A. | Interim CFO | 1957 (67 years) | |
Mr. Kevin Bitter | VP of Strategy & Corporate Development | 1992 (32 years) | |
Dr. Julie Clark M.D., M.S. | Senior Vice President of Clinical Development | 1975 (49 years) |
Address: Australia, South Yarra. VIC, 650 Chapel Street - open in Google maps, open in Yandex maps
Website: https://www.opthea.com
Website: https://www.opthea.com